Molecular decoys: antidotes, therapeutics and immunomodulators

The Screening of Herbals as Immunomodulators in Therapeutics: a Review

Molecular Targets and Cancer Therapeutics

PR01 Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer. Giulia Siravegna, Mariangela Russo, Lawrence S. Blaszkowsky, Giorgio Corti, Giovanni Crisafulli, Leanne G. Ahronian, Benedetta Mussolin, Eunice L. Kwak, Michela Buscarino, Luca Lazzari, Emanuele Valtorta, Mauro Truini, Nicholas A. Jessop, Hayley E. Robinson, Theod...

Molecular Targets and Cancer Therapeutics

LB-A01 Molecular subgroup analysis of a randomized trial (EORTC 26082-22081) testing temsirolimus and radiation therapy versus chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma without methylation of the MGMT gene promoter. Monika E. Hegi, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin JB Taphoorn, Jonathan Steuve, Alba A. Brandes, M...

Liposarcoma: Molecular Genetics and Therapeutics

Sarcomas are a group of heterogeneous tumours with varying genetic basis. Cytogenetic abnormalities range from distinct genomic rearrangements such as pathognomonic translocation events and common chromosomal amplification or loss, to more complex rearrangements involving multiple chromosomes. The different subtypes of liposarcoma are spread across this spectrum and constitute an interesting tu...

Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines

Some bovine antibodies across all classes are unique, such as the CDR3 of the variable heavy-domain (VH CDR3), which is exceptionally long (up to 66 amino acids), unlike most conventional antibodies where the VH CDR3 loops range from 10 to 25 amino acids. The exceptionally long VH CDR3 is encoded by unusually long germline IGHD genes together with insertion of novel “a” nucleotide rich conserve...